Loading clinical trials...
Loading clinical trials...
Valved Graft Post-Market Clinical Follow-up Study
Multicenter, global, prospective, non-randomized, interventional, post-market trial. All subjects enrolled will receive an Abbott Valved Graft device.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
University Hospital - Univ. of Alabama at Birmingham (UAB)
Birmingham, Alabama, United States
University of Michigan
Ann Arbor, Michigan, United States
Mission Health & Hospitals
Asheville, North Carolina, United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Klinik Floridsdorf
Vienna, Austria
Rigshospitalet
Copenhagen, Denmark
CHU de Besancon - Jean Minjoz
Besançon, France
CHRU Lille
Lille, France
Groupe Hospitalier Bichat - Claude Bernard
Paris, France
Start Date
July 13, 2021
Primary Completion Date
July 1, 2029
Completion Date
September 1, 2029
Last Updated
July 16, 2025
260
ESTIMATED participants
VAVGJ
DEVICE
CAVGJ
DEVICE
Lead Sponsor
Abbott Medical Devices
NCT07366671
NCT06455787
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06352671